Magnesium for GLP-1-Induced Constipation: Evidence, Mechanisms, and Our Top Picks for 2026

The osmotic mechanism of magnesium in the colon begins after the mineral bypasses absorption in the small intestine. Magnesium is absorbed primarily in the small intestine, with absorption efficiency varying by form (citrate approximately 30% absorbed versus oxide approximately 4%). The unabsorbed fraction — which increases as total dose increases — passes into the large intestine. Once in the colon, magnesium ions create an osmotic gradient: because the colonic lumen now has a higher solute concentration than the surrounding colonic tissues, water is drawn across the colonic mucosa into the lumen by osmosis. This water increase softens stool directly (reducing hardness and improving passage) and stretches the colon wall as stool volume increases. The mechanical stretch of colonic smooth muscle activates peristaltic contractions through the myenteric plexus, helping propel stool forward. In the GLP-1 constipation context, this mechanism maps directly onto the deficit: GLP-1 agonists reduce peristaltic contractions and reduce the fluid reaching the colon from gastric emptying — resulting in slower transit and greater water reabsorption from stool, producing dry, hard stools. Magnesium citrate restores fluid balance in the colonic lumen and mechanically stimulates the peristalsis that GLP-1 receptor activation has suppressed. The citrate anion also plays a role in the overall tolerability profile. Compared to magnesium oxide (which has very poor bioavailability and causes a large unabsorbed fraction to reach the colon rapidly, producing a more abrupt laxative effect), the citrate salt's intermediate bioavailability produces a gentler, more controllable osmotic effect at standard supplemental doses. This titratability is important for GLP-1 users, whose baseline GI sensitivity may be altered by the medication.

Choosing a magnesium supplement for GLP-1-induced constipation requires thinking about form, dose, and timing differently than you would for general mineral supplementation: **Citrate is the preferred form here — not oxide.** Magnesium oxide is the cheapest and most common form but has approximately 4% bioavailability — meaning most of it reaches the colon as an unabsorbed lump, producing an abrupt and often cramping laxative effect. For GLP-1 users whose GI tract is already sensitive and slower-moving, this abruptness is undesirable. Magnesium citrate with approximately 30% bioavailability produces a gentler, more titratable osmotic effect. **Powder versus tablet.** For users new to magnesium supplementation or with unpredictable GLP-1 GI effects, powder format (like Natural Vitality CALM) allows you to adjust the dose in small increments. Tablets require cutting or skipping whole units to adjust. If your GI tolerance is well-established and you want convenience, a single-softgel option (Nature Made) may be preferable. **Timing with meals.** Taking magnesium with food generally slows absorption, which moderates the osmotic effect — useful if you want a gentler, delayed action. Taking it with a large glass of water on an empty stomach produces faster and stronger laxative action. GLP-1 users who find the medication has already made them nauseous should take magnesium with a small amount of food to avoid compounding nausea. **Titrate up slowly.** Start at 100–150mg elemental magnesium and increase over 1–2 weeks until you find the dose that produces adequate stool softening without loose stools. The target is relief from constipation, not diarrhoea — both extremes are uncomfortable and the right dose sits in between. **Fluid intake matters.** The osmotic mechanism of magnesium requires water to draw into the colon. If you are not adequately hydrated — which is common in GLP-1 users whose appetite suppression also reduces habitual fluid intake — the effect will be diminished and you risk worsening dehydration. Aim for adequate daily fluid intake regardless of magnesium use.